# Shanghai Neutan Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-neutan-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.neutanpharma.com
- Total disclosed funding: $31M
- Latest round: Series A (Mar 29, 2022)
- Investors on record: 5

## About

Based in Shanghai, China, and established in 2019, Shanghai Neutan Pharmaceutical Co., Ltd. is a pharmaceutical company that provides drug development and manufacturing services. The company's founding team is from Shanghai Fosun Pharmaceutical (Group), WuXi AppTec Group, Roche. The company has an R&D center in Shanghai and has additional offices in Anhui, Zhejiang, and Shandong. The R&D center covered 3,000 square meters and passed the standards of CNAS, and GMP.   

The company provides services and solutions that include drug substance development and manufacturing, analytical development and quality control, drug product development and manufacturing, and global regulatory affairs CMC filing. The company supports active pharmaceutical ingredient (API) reach and development and production projects from laboratory scale and to commercial scale.

The company plans to use the series A funding to continue to establish drug substances and drug product production bases, and improve the R&D systems.

## Funding rounds

- Series A, Mar 29, 2022, $31M — Grand Yangtze Capital, HighLight Capital, Addor Capital, Step Fund
- Angel, Jun 22, 2021 — Lanwan Venture Capital

## Investors

- Lanwan Venture Capital (https://capitalatlas.ai/funds/lanwan-venture-capital) — Angel
- Grand Yangtze Capital (https://capitalatlas.ai/funds/grand-yangtze-capital) — Series A
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- Step Fund (https://capitalatlas.ai/funds/step-fund) — Series A